Rein Therapeutics
RNTX
36 hedge funds and large institutions have $9.54M invested in Rein Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 8 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
2.28% more ownership
Funds ownership: 27.77% → 30.05% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 39 → 36 (-3)
10% less capital invested
Capital invested by funds: $10.6M → $9.54M (-$1.1M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$798K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$301K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$86.4K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$59.8K |
| 5 |
GG
Gleason Group
Prospect,
Kentucky
|
+$40.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$101K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$51.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$28.8K |
| 4 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$19.8K |
| 5 |
Morgan Stanley
New York
|
-$7.61K |
RNTX Hedge Fund Activity: Q2 2025 in Review
36 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2025, worth a combined $9.54M — down 10% from $10.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RNTX and 5 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Voss Capital, adding an estimated $798K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $101K sold.
- 36 institutional investors held Rein Therapeutics (RNTX) as of Q2 2025, down from 39 in Q1 2025.
- Funds reported $9.54M of Rein Therapeutics stock for Q2 2025, down 10% quarter-over-quarter.
- 5 funds opened new Rein Therapeutics positions in Q2 2025 and 8 closed out, a net change of -3 holders.
- The largest Rein Therapeutics buyer in Q2 2025 was Voss Capital, an estimated $798K added.
- The largest Rein Therapeutics seller in Q2 2025 was Royal Bank of Canada, an estimated $101K sold.
Based on aggregated 13F filings for Q2 2025.